Deep Track reports 6.17% stake in Nurix Therapeutics

Nurix Therapeutics ownership filing: Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report beneficial ownership of 6,345,244 shares of Common Stock, representing 6.17% of the class as of 03/31/2026.

Rhea-AI Filing Summary

Nurix Therapeutics ownership filing: Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report beneficial ownership of 6,345,244 shares of Common Stock, representing 6.17% of the class as of 03/31/2026. The filing states this share count is based on 102,843,012 shares outstanding as of 01/23/2026. The statement is a joint filing under Rule 13d-1(k) and identifies Deep Track Capital, LP as the relevant entity for which Mr. Kroin may be considered a control person.

Insights

Corporate Governance Analyst

13G amendment reports a passive stake of 6,345,244 shares (6.17%).

The filing documents that the reported 6,345,244 shares are held with shared voting and dispositive power, consistent with passive/beneficial reporting under Schedule 13G/A. It cites the issuer's 10-K for an outstanding share base of 102,843,012 shares as of 01/23/2026.

Stakeholders should note the joint-filing language and the identification of Deep Track Capital, LP as the relevant entity; subsequent amendments will be filed on behalf of all reporting persons.

Investor Relations Advisor

The filing clarifies ownership scale but does not disclose transactions or plans.

The statement is informational: it lists shared voting/dispositive power and the beneficial count but does not describe purchases, sales, or an intent to influence corporate actions. It therefore gives readers a clear ownership snapshot without change-of-control language.

Future amendments may update holdings; timing and cash-flow treatment are not included in the excerpt.

Key Figures

Beneficial ownership: 6,345,244 shares Percent of class: 6.17% Shares outstanding used: 102,843,012 shares +1 more

4 metrics

Beneficial ownership 6,345,244 shares Amount beneficially owned as of 03/31/2026

Percent of class 6.17% Percent of Common Stock based on outstanding shares

Shares outstanding used 102,843,012 shares Outstanding as of 01/23/2026 per issuer 10-K

Shared voting/dispositive power 6,345,244 shares Shared power to vote and dispose reported in Item 4

Key Terms

Schedule 13G/A, Beneficial ownership, Shared dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 2 — joint filing under Rule 13d-1(k)"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficial ownership financial

"Amount beneficially owned: 6,345,244 (b) Percent of class: 6.17%"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Shared dispositive power financial

"Shared Dispositive Power 6,345,244.00 reported in Item 4"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Deep Track report in Nurix Therapeutics (NRIX)?

Deep Track reports beneficial ownership of 6,345,244 shares, equal to 6.17% of the class, as stated for the period ending 03/31/2026. The percent is calculated using an outstanding share base of 102,843,012 reported as of 01/23/2026.

Who is the filing made on behalf of in the Schedule 13G/A?

The joint filing is made by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin. The document identifies Deep Track Capital, LP as the relevant entity for which Mr. Kroin may be a control person.

Does the filing indicate whether the stake is passive or active?

The filing is a Schedule 13G/A amendment and reports shared voting and dispositive power without change-of-control language, consistent with a passive/beneficial reporting posture. It does not state plans to acquire additional shares or exert control.

What share count and outstanding base are used to compute the percentage?

The percent (6.17%) is based on 6,345,244 shares beneficially owned and an outstanding share base of 102,843,012 Common Stock as of 01/23/2026, per the issuer's 10-K referenced in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 08:45 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Nurix Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

67080M103

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 67080M103

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,345,244.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,345,244.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,345,244.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.17 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 67080M103

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,345,244.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,345,244.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,345,244.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.17 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 67080M103

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,345,244.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,345,244.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,345,244.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.17 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Nurix Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1600 Sierra Point Parkway, Brisbane, CA 94005
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 67080M103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6,345,244
(b)	Percent of class: 6.17%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 6,345,244
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 6,345,244
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	05/15/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	05/15/2026

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	05/15/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of March 31, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 102,843,012 Common Stock outstanding as of January 23, 2026, according to the issuer's 10-K filed with the SEC on January 28, 2026. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin